NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's Positive Phase 2a Results for SGX945 in Behçet's Disease
TL;DR
Soligenix's SGX945 shows comparable efficacy to apremilast with only four weeks of dosing, offering a potential competitive advantage in treating Behçet's Disease ulcers.
SGX945 demonstrated beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up after treatment ended, with no treatment-related adverse events observed.
This treatment could significantly improve quality of life for Behçet's Disease patients by reducing oral ulcers and pain while addressing an unmet medical need.
Soligenix's novel drug SGX945 achieved results comparable to an established Phase 3 treatment with just four weeks of dosing instead of continuous administration.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix has published positive Phase 2a proof-of-concept study results for SGX945 (dusquetide) in treating aphthous ulcers associated with Behçet's Disease, showing beneficial effects in most patients with sustained improvement after treatment ended.
The study showed beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended, including reductions in oral ulcers and pain, with favorable area under the curve measurements.
Outcomes for SGX945 were comparable to those reported in a Phase 3 study of apremilast (Otezla®), despite SGX945 dosing stopping at Week 4 while apremilast requires continuous administration.
SGX945 was well tolerated with no treatment-related adverse events observed in the Phase 2a study.
Soligenix plans to pursue reformulation to enable home-based subcutaneous administration, expand development of dusquetide across additional innate immune-related inflammatory conditions, and engage regulators on a follow-on clinical study.
Soligenix is developing HyBryte™ for cutaneous T-cell lymphoma, synthetic hypericin for psoriasis, dusquetide for oral mucositis in head and neck cancer, and has vaccine programs for ricin toxin, filoviruses, and COVID-19.
The full press release is available at https://ibn.fm/ibHfU, and the latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, with two business segments: Specialized BioTherapeutics and Public Health Solutions.
Curated from InvestorBrandNetwork (IBN)
